Preventing an anesthetic-associated movement is a specific endpoint, not proof of comprehensive safety.
In a three-group study, myoclonus after etomidate was less frequent with fentanyl–midazolam pretreatment than with either pretreatment alone. Moderate or severe movements were also less frequent with the combination.
The comparison did not include an untreated control. It concerned particular pretreatment regimens and cannot establish that all observed movements were epileptic or that the combination prevents every adverse event.
Describe myoclonus separately from a confirmed seizure. In a case reconstruction, align induction drugs, movements, vital signs and any EEG evidence. A reduced movement rate does not establish that the additional sedatives carry no respiratory burden or explain the mechanism of an individual event.
Source: PMC7932701, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Etomidate–Midazolam Versus Propofol–Ketamine in Patients With Reduced Ejection Fraction.